Day: December 5, 2019

Surpasses $500 million in ARR and achieves positive cash flow from operations and free cash flowIncreases full year revenue outlookSubscription revenue grew 98% year-over-year to $114.2 millionARR grew 97% year-over-year to $501.7 millionRecord net new ARR of $77.9 million, increased 32% quarter-over-quarterSubscription customers increased 112% year-over-year to reach 4,561 customersGenerated $38.6 million in cash from operations and $7.0 million in free cash flowSUNNYVALE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) — CrowdStrike Holdings, Inc., (Nasdaq: CRWD), a leader in cloud-delivered endpoint protection, today announced financial results for the third quarter of its fiscal 2020, ended October 31, 2019.“Third quarter results well exceeded our expectations and CrowdStrike delivered the best quarter yet in company history with strength...

HOUSTON, Dec. 05, 2019 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (“W&T” or the “Company”) announced today that the Company has recently added new West Texas Intermediate crude oil hedge positions for the period from June 2020 through December 2020.   These additional positions include: A complete summary of the Company’s currently outstanding crude oil and natural gas derivative positions is included in the table below.Tracy W. Krohn, Chairman and Chief Executive Officer, commented, “We are pleased with these additional crude oil hedge positions that enhance our previously-existing positions in 2020.  We believe our expanded hedge portfolio will provide us with increased cash flow stability in 2020 and beyond as we continue to pursue our strategy of being opportunistic while maintaining strong free cash flow.”About...

Kingsport, Tenn., Dec. 05, 2019 (GLOBE NEWSWIRE) — The Board of Directors of Eastman Chemical Company (NYSE: EMN) has declared a quarterly cash dividend of $0.66 per share on the company’s common stock, a 6.5 percent increase from $0.62 per share. The dividend is payable Jan. 3, 2020, to stockholders of record as of Dec. 16, 2019.“Consistent with Eastman’s focus on balanced and disciplined capital allocation and stockholder returns, I am pleased that the company has each year for the past decade increased the dividend,” said Curt Espeland, executive vice president and chief financial officer. “This action reflects the Board’s confidence in our ability to deliver earnings growth and strong cash flow generation.”Eastman is a global specialty materials company that produces a broad range of products found in items people use...

GUADALAJARA, Mexico, Dec. 05, 2019 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacifico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announced preliminary terminal passenger traffic figures for the month of November 2019, compared to traffic figures for November 2018.During November 2019, total terminal passengers at GAP’s 14 airports increased by 10.1%, compared to the same period of the previous year. Domestic passenger traffic increased by 7.5%, while international passenger traffic increased by 13.6%.*Passengers in Tijuana who use CBX in both directions are classified as international.Highlights for the Period:Seats and Load Factors:  In November 2019, the number of seats available increased by 6.7% compared to November 2018; while load factor for the month increased by 3.0 percentage points, from 80.8% in...

TORONTO, Dec. 05, 2019 (GLOBE NEWSWIRE) — Partners Real Estate Investment Trust (the “REIT” or “Partners”) (TSX: PAR.UN) announced today that the plan of arrangement pursuant to which McCowan and Associates Ltd. (“MAA”) will, among other things, acquire all of the outstanding units of the REIT (each, a “Unit”), except for the 9,229,704 Units (representing approximately 20.03% of the outstanding Units) held by MAA, for a price of $0.78 in cash per Unit (the “Arrangement”) was approved by its holders of Units (“Unitholders”) at a special meeting of Unitholders held on December 5, 2019 (the “Meeting”).The Arrangement required approval by the affirmative vote of: (i) at least two-thirds of the votes cast by Unitholders; and (ii) at least a majority of the votes cast by Unitholders excluding those Unitholders whose votes were required...

LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson’s disease-focused R&D Day on December 13, 2019 from 9:00-11:30 a.m. ET in New York. The program will focus on MeiraGTx’s investigational gene therapy candidate AAV-GAD in development for the treatment of Parkinson’s disease.The day will consist of speaker presentations, a moderated panel, and an audience Q&A session. MeiraGTx’s president and CEO, Alexandria Forbes, Ph.D., will be joined by additional members of the senior leadership team, in addition to leading clinicians and researchers, to discuss the current Parkinson’s disease treatment landscape and results from Phase 1 and Phase 2 clinical trials of AAV-GAD.Featured guests...

POMPANO BEACH, Fla., Dec. 05, 2019 (GLOBE NEWSWIRE) — Basanite Industries LLC (OTC: BASA) (hereinafter “Basanite”) has received its permit to power up and begin all phases of calibration, material verification and testing to produce BasaFlexTM, its enhanced basalt fiber reinforced polymer (BFRP) designed to replace steel reinforcement in concrete structures.BasaFlexTM addresses a significant problem in the replacement of failing infrastructure – concrete corrosion caused by steel reinforcement. As a non-corrosive reinforcement that is one-quarter the weight of steel and has high tensile strength, BasaFlexTM is designed to meet specifiers’ demands for longer-lasting concrete components when they are rebuilding or replacing infrastructure, according to Richard Krolewski, Basanite CEO.“State departments of transportation and local...

LONDON, Dec. 05, 2019 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL) announced today that management will host a conference call and webcast on Monday, December 9, 2019 at 8:30 am ET / 1:30 pm GMT to review clinical data presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition. Conference Call InformationTo listen to the webcast and view the accompanying slide presentation, please go to https://www.autolus.com/investor-relations/news-events/events.The call may also be accessed by dialing 866-679-5407 (U.S.) or 409-217-8320 (international) and referencing conference ID 9796038.After the conference call, a replay will be available for one week. To access the replay, please dial 855-859-2056 (U.S.) or 404-537-3406 (international) and enter conference ID 9796038.About Autolus Therapeutics...

HOUSTON, Dec. 05, 2019 (GLOBE NEWSWIRE) — Harvest Oil & Gas Corp. (OTCQX: HRST) (“Harvest” or the “Company”) announced today that its board of directors has approved a share repurchase program under which Harvest is authorized to repurchase up to $5.0 million of its outstanding common stock.Share repurchases may be made from time to time, at the Company’s discretion, through open market repurchases or negotiated transactions, which may be effected through Rule 10b5-1 trading plans. The Company intends to fund repurchases from cash on hand. This program is intended to continue the Company’s commitment to shareholder returns and the efficient management of the Company’s assets, including cash on hand.Repurchases by the Company will be subject to general market and economic conditions, alternate uses for the capital and other...

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic, AL001, for the treatment of patients with frontotemporal dementia (FTD) carrying specific genetic mutations in the granulin gene (FTD-GRN). AL001 is the company’s product candidate currently being evaluated in a Phase 2 trial for the treatment of FTD-GRN and FTD-C9orf72.Fast Track designation is designed to facilitate the development and expedite the review of therapies for serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority...